​​​​​​ ​​​​​​​​​​​​​​​​​​
otlogo.png
​​

​​​Lung Cancer Resource Center

​Focus On NSCLC

ctDNA Analysis for Mutations Causing Lung Cancer Treatment Resistance

​While chemotherapy and radiation remain therapy foundations for patients with locoregionally advanced and metastatic disease, the genetic mechanisms that lead to chemotherapy and radiation resistance are unclear because of a lack of available tissue at the time of relapse. 

Read More >

New Drug Effective Against Lung Cancers Caused By Common Genetic Error

The results of the CODEBREAK 100 Phase II clinical trial were presented at the 2021 ASCO Annual Meeting (Abstract 9003) and published simultaneously in the New England Journal of Medicine (2021;doi: 10.1056/NEJMoa2103695). The efficacy and safety of the drug sotorasib was tested in patients with non-small-cell lung cancer (NSCLC) harboring a specific change, or mutation, in the DNA code for KRAS.

Read More >

Urine Metabolites Can Predict When Lung Cancer Patients Will Die

What if you could predict with 88 percent certainty when a lung patient cancer may die? Researchers from the University of Liverpool confirmed urine metabolites can predict when people with lung cancer are in the last weeks and days of life and presented study results at ASCO 2021 (Abstract 12030). 

Read More >

MET Amplification: Key Driver in Some Non-Small Cell Lung Cancers

 A clinical study has concluded that amplification of the mesenchymal–epithelial transition (MET) gene (involved with embryonic development) is a driver for a subset of non-small cell lung cancers (NSCLC) and should be included along with other molecular profiling tests in more patients to help with therapy decision-making (J Thorac Oncol 2021 doi: 10.1016/j.jtho.2021.02.010).​

​Read More >

VIOLET Trial Examines VATS Vs. Open Lobectomy for Early-Stage Lung Cancer

For the majority of patients with early-stage lung cancer, surgical resection remains the only effective means of cure. 

Read More >

​​

Fill out my online form.
Fill out my online form.